Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 5/20 | 0.42 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.42 |
| ▸ | FYN | P06241 | 2/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | ATR | Q13535 | 2/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13271698 | 0.89 | PIK3CA (0.42) | MAP4K4MINK1TNIKPIK3CAAKT1 | |
| SCHEMBL3115836 | 0.89 | PIK3CA (0.51) | MAP4K4MINK1FYNTNIKPIK3CA | |
| SCHEMBL3117706 | 0.88 | PIK3CA (0.40) | MAP4K4MINK1TNIKPIK3CAAKT1 | |
| SCHEMBL3119875 | 0.88 | PIK3C3 (0.40) | PIK3CAAKT1PIK3C3ATRALOX5AP | |
| SCHEMBL3121364 | 0.87 | PIK3CA (0.43) | MAP4K4MINK1TNIKPIK3CAAKT1 | |
| SCHEMBL3121729 | 0.84 | CA9 (0.42) | MAP4K4PIK3CAAKT1PIK3C3MTOR | |
| SCHEMBL3112863 | 0.84 | LRRK2 (0.38) | MAP4K4PIK3CAAKT1KCNH2PIK3C3 | |
| SCHEMBL3121488 | 0.79 | MAP4K4 (0.38) | MAP4K4PIK3CAKCNH2PIK3C3MTOR | |
| SCHEMBL3110852 | 0.78 | PIK3CA (0.42) | FYNPIK3CAAKT1PI4KBPIK3C3 | |
| SCHEMBL3108650 | 0.73 | PIK3C3 (0.44) | MAP4K4MINK1TNIKPIK3CAAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179143-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100179143-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| EP-2154965-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | Glaxosmithkline LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008150827-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179143-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | INPP5D, PI4KA, PTEN | MAP4K4 661/4885MINK1 536/4885FYN 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.